Biotech strategy notes

This page covers recurring decision problems biotech leadership teams face when moving from scientific plausibility to fundable, executable strategy.

Supplementary context. For current product positioning, start with What we do and Portfolio Intelligence System. This note remains useful for framing but is not a substitute for those offers.

Core decision problems

• Which target-indication pairing has the strongest evidence-adjusted upside?
• Where is differentiation realistic versus crowded mechanisms?
• What is the shortest path to an investor-ready narrative without overclaiming?

Practical approach

• Anchor choices in reproducible evidence (target, disease, drug, and mechanism context).
• Separate biological conviction from commercial feasibility.
• Use explicit trade-offs: indication depth vs speed, novelty vs competition.

Suggested next reading

• For startups
• Biotech target decision framework
• Contact for scoped deliverables